Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Limited filed a Form 6-K as a foreign private issuer for August 2025 to furnish two announcements previously published on the Australian Securities Exchange. These ASX notices, titled Appendix 3G, are attached, including Exhibit 99.2, a notification regarding unquoted securities for IMC.
Immuron Limited furnished a Form 6-K reporting that it published two public notices to the Australian Securities Exchange titled "Emerging Growth Conference Presentation". The filing states that a copy of the presentation is attached to the Form 6-K as Exhibit 99.2.
The Form 6-K clarifies that this submission and the attached exhibit are furnished for information only and are not deemed to be "filed" under the U.S. Exchange Act, and therefore are not incorporated by reference into other securities filings except by explicit reference. The report is signed on behalf of the company by its Company Secretary.